Search

Your search keyword '"Fielding, Anitra"' showing total 5 results
Start Over Author "Fielding, Anitra" Database Supplemental Index
5 results on '"Fielding, Anitra"'

1. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.

Author

Meric-Bernstam, Funda, Makker, Vicky, Oaknin, Ana, Oh, Do-Youn, Banerjee, Susana, González-Martín, Antonio, Jung, Kyung Hae, Ługowska, Iwona, Manso, Luis, Manzano, Aránzazu, Melichar, Bohuslav, Siena, Salvatore, Stroyakovskiy, Daniil, Fielding, Anitra, Ma, Yan, Puvvada, Soham, Shire, Norah, and Lee, Jung-Yun

Published
2024
Full Text
View/download PDF

2. Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.

Author

Yung-Jue Bang, Seock-Ah Im, Keun-Wook Lee, Jae Yong Cho, Eun-Kee Song, Kyung Hee Lee, Yeul Hong Kim, Joon Oh Park, Hoo Geun Chun, Dae Young Zang, Fielding, Anitra, Rowbottom, Jacqui, Hodgson, Darren, O'Connor, Mark J., Xiaolu Yin, Woo Ho Kim, Bang, Yung-Jue, Im, Seock-Ah, Lee, Keun-Wook, and Cho, Jae Yong

Published
2015
Full Text
View/download PDF

4. Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II).

Author

Hoff, Paulo M., Hochhaus, Andreas, Pestalozzi, Bernhard C., Tebbutt, Niall C., Jin Li, Tae Won Kim, Koynov, Krassimir D., Kurteva, Galina, Pintér, Tamás, Ying Cheng, van Eyll, Brigitte, Pike, Laura, Fielding, Anitra, Robertson, Jane D., and Saunders, Mark P.

Published
2012
Full Text
View/download PDF

5. Olaparib Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Serous Ovarian Cancer

Author

Ledermann, Jonathan, Harter, Philipp, Gourley, Charlie, Friedlander, Michael, Vergote, Ignace, Rustin, Gordon, Scott, Clare L., Meier, Werner, Shapira-Frommer, Ronnie, Safra, Tamar, Matei, Daniela, Fielding, Anitra, Spencer, Stuart, Dougherty, Brian, Orr, Maria, Hodgson, Darren, Barrett, J. Carl, and Matulonis, Ursula

Abstract

Greater than 20 of cases of high-grade serous ovarian cancer are due to germline or somatically acquired BRCAmutations. Poly(ADP-ribose) polymerase inhibitors have been investigated as treatment for a number of tumors, including those due to BRCAmutations. One potent oral poly(ADP-ribose) polymerase inhibitor, olaparib, has shown antitumor activity in patients with both BRCAand sporadic high-grade serous ovarian cancer. A previous randomized, double-blind, placebo-controlled phase 2 study showed that twice-daily maintenance treatment with oral olaparib in patients with platinum-sensitive recurrent serous ovarian cancer significantly improved progression-free survival (PFS). Subgroup analysis suggested that olaparib may increase PFS longer in patients with known BRCA status than in those with unknown mutation status.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results